
Targentra™ is a modular platform designed to conditionally deliver drugs inside cancer cells using one target shared across multiple solid tumors. Conventional antibody–drug conjugates (ADCs) rely on internalizing targets, also expressed on healthy cells, where ADC uptake can cause severe side effects. Targentra™ uses underused, non-internalizing tumor-localized targets and is designed to deliver intact conjugates into cancer cells for intracellular drug release, potentially reducing healthy-tissue exposure.
See the full profile
The pitch deck, traction, financials and competitive detail are visible to approved investors, mentors and corporates. Log in or join EndCancer.Life to request access.
Send a short message. We’ll pass it to Conqueror Biopharma with your name and email, so they can reply.
Create an account or log in to send this request. Already a member? Log in
Introductions to innovators are open to innovators, investors, mentors and corporates.